股票近期走势 以上内容基于公开资料整理，不构成投资建议。 财报分析 经济观察网持股5%以上股东美国联合生物医药公司(UBI)完成减持申联生物股份（600201）12,319,240 股(占公司总股本3%)，减持后持股比例从10.52%降至7.52%。减持价格区间为8.80-9.89元/股，总金额约 1.11亿元。本次减持计划自2025年11月13日启动，于2026年2月9日实施完毕，不会导致公司控股股东或 实际控制人变更。公司于2026年1月23日披露业绩预告，预计2025年归母净亏损约2000万元，较2024年 亏损收窄约55%；扣非净亏损约2350万元，收窄约51%。亏损收窄主要得益于降本增效，但动保行业竞 争加剧导致产品单价下降、应收账款减值损失增加及新车间折旧上升。 2025年业绩预亏主要反映主营业务承压：行业价格战导致销售收入和毛利率小幅下滑，同时客户回款延 迟致信用减值损失上升，新疫苗车间转固增加折旧。尽管公司通过优化销售费用及研发聚焦(如多联疫 苗进展)减亏，但自2021年起净利润已连续五年下滑，现金流压力仍存。 近7天(2026年2月5日至11日)，申联生物股价区间涨跌幅为3.63%，最高价9 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has released the "Technical Guidelines for Clinical Trials of Multivalent Vaccines" to support the high-quality development of the vaccine industry and accelerate the research and market launch of domestic multivalent vaccines [1] Group 1: Guidelines Overview - The guidelines include considerations for topic selection, clinical trial design, and post-marketing changes, specifically applicable to the clinical development of multivalent vaccines [1] Group 2: Importance of Multivalent Vaccines - Multivalent vaccines contain antigens related to different pathogens and are defined based on biological taxonomy by "species" [1] - These vaccines simplify immunization schedules, reduce the number of vaccinations required, and enhance the convenience and compliance of vaccination, which is crucial for increasing vaccination rates and alleviating public health burdens [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [5][10]. Core Insights - The company reported a significant increase in revenue and profit for the first half of 2025, with operating income reaching 1.708 billion yuan, a year-on-year growth of 20.53%, and a net profit attributable to shareholders of 257 million yuan, up 57.59% [3][4]. - The economic animal health segment is performing steadily, while the pet health segment is emerging as a new strategic direction, contributing to long-term growth [5][4]. - The company is focusing on large customer strategies and has established strategic partnerships with leading breeding groups, enhancing its market share through brand strength and product quality [4]. Financial Summary - The company expects its earnings per share (EPS) to be 0.99 yuan, 1.27 yuan, and 1.40 yuan for the years 2025, 2026, and 2027 respectively [5][6]. - Projected operating revenues for 2024 to 2027 are 3.070 billion yuan, 3.650 billion yuan, 4.221 billion yuan, and 4.692 billion yuan, with growth rates of 13.32%, 18.90%, 15.64%, and 11.14% respectively [6][9]. - The company's net profit attributable to shareholders is forecasted to be 300.72 million yuan in 2024, increasing to 650.39 million yuan by 2027, reflecting a growth rate of -33.70% in 2024 followed by positive growth in subsequent years [6][9].